Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accumulated Expenses (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Accumulated Expenses for 6 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 30.0% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, down 30.0% year-over-year, with the annual reading at $16.5 million for FY2025, 30.0% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $16.5 million at Caribou Biosciences, down from $19.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $25.4 million in Q3 2024, with the low at $11.2 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $17.5 million, with a median of $16.5 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses skyrocketed 51.39% in 2024, then fell 30.0% in 2025.
  • Over 5 years, Accumulated Expenses stood at $13.1 million in 2021, then grew by 22.4% to $16.1 million in 2022, then soared by 31.44% to $21.1 million in 2023, then grew by 11.76% to $23.6 million in 2024, then decreased by 30.0% to $16.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $16.5 million, $19.3 million, and $20.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.